{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:47:43Z","timestamp":1761511663574},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1313,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To study the effects of long\u2010term growth hormone (GH) treatment on lipid metabolism and carbohydrate tolerance in GH\u2010deficient adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN<\/jats:title><jats:p>Open trial of GH treatment for 4 years. GH dose was (median, range) 0.025 (0.010\u20130.050) IU\/kg daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS<\/jats:title><jats:p>Thirteen GH\u2010deficient hypopituitary adults (seven men, six women), aged (median, range) 47 (24\u201365) years were followed for 4 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>MEASUREMENTS<\/jats:title><jats:p>Fasting lipids, lipoproteins, apolipoproteins, glucose and insulin concen_trations were measured at yearly intervals during GH therapy. A 75\u2010g oral glucose tolerance test (OGTT) was also performed yearly, during which circulating glucose and insulin were measured at 30\u2010minute intervals for 3\u2003h.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Fasting total and low density lipoprotein (LDL) cholesterol concen_trations decreased on GH therapy, but no change was observed in fasting triglyceride or high density lipoprotein (HDL) concen_trations. Compared to pretreatment values, total and LDL cholesterol levels were significantly lower at 1 year (mean\u2003\u00b1\u2003SEM) (6.39\u2003\u00b1\u20030.46 vs. 5.71\u2003\u00b1\u20030.38\u2003mmol\/l, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05; 4.46\u2003\u00b1\u20030.36 vs. 3.24\u2003\u00b1\u20030.20\u2003mmol\/l, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01, respectively) and the reductions were maintained for the 4 years. Apolipoproteins A\u20101 and B did not differ significantly from the pretreatment levels. Fasting plasma glucose increased significantly at the first year (4.9\u2003\u00b1\u20030.1 vs. 5.3\u2003\u00b1\u20030.1\u2003mmol\/l, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) but it returned to the pretreatment value in the following years. Fasting plasma insulin increased significantly at 1 year (4.3 (1.0\u201313.6) vs. 11.9 (1.2\u201326.9) mU\/l, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) and showed a progressive downward trend but remained significantly raised throughout the subsequent years. The 3\u2010h area under the glucose curve (AUC) during the OGTT tended to be increased at the first year (<jats:italic>P<\/jats:italic>\u2003=\u20030.07) and it returned to the pretreatment level in the following years. The AUC of plasma insulin was significantly raised at 1 year (<jats:italic>P<\/jats:italic>\u2003=\u20030.024) and it returned to the pretreatment level in the following years.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Four years of GH therapy in GH\u2010deficient adults resulted in a sustained improvement in total and LDL cholesterol concen_trations. Mild fasting hyperinsulinaemia persisted, although an initial deterioration in glucose tolerance, associated with post\u2010glucose hyperinsulinaemia, was not sustained.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1998.00460.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:36:45Z","timestamp":1047379005000},"page":"795-802","source":"Crossref","is-referenced-by-count":60,"title":["Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH\u2010deficient adults"],"prefix":"10.1111","volume":"48","author":[{"given":"Kamal A. S.","family":"Al\u2010Shoumer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Anyaoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem","family":"Beshyah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond G.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1350559"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.d01-1552.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2653"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.3.1169"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.2.309"},{"key":"e_1_2_7_7_2","first-page":"173","article-title":"Metabolic abnormalities in growth hormone deficient adults II: carbohydrate tolerance and lipid metabolism","volume":"1","author":"Beshyah S.A.","year":"1994","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.2.356"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02287.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(82)90121-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(93)90145-E"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-8-2-115"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90245-3"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.13.2.296"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(69)90327-4"},{"key":"e_1_2_7_16_2","first-page":"121","article-title":"Increased cardiovascular mortality in patients with hypopituitarism","volume":"3","author":"Erfurth E.M.","year":"1996","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-30-3-288"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1340061"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/diab.35.5.612","article-title":"Insulin and C\u2010peptide levels after oral and intravenous glucose","volume":"35","author":"Hampton S.M.","year":"1986","journal-title":"Diabetes"},{"key":"e_1_2_7_20_2","first-page":"143","article-title":"Effects of 18 months of recombinant human growth hormone treatment on lipid metabolism in pituitary\u2010insufficient patients","volume":"2","author":"H\u00e4rle U.","year":"1995","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_7_21_2","first-page":"189","article-title":"The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours","volume":"202","author":"Jadresic A.","year":"1982","journal-title":"Quaternary Journal of Medicine"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90292-9"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92328-3"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199001000-00004"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0560593"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(72)90036-4"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109734"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00805.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.4.975"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.7.2448"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90293-0"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91812-O"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1290195"},{"key":"e_1_2_7_34_2","first-page":"55","article-title":"Beneficial effects of 12 months replacement with recombinant human growth hormone to growth hormone deficient adults","volume":"1","author":"Ros\u00e9n T.","year":"1994","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02555.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212605"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0870201"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90001-9"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-27-10-1418"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1991.tb12064.x"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(67)90056-X"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-51-3-626"},{"key":"e_1_2_7_43_2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/28.6.1379","article-title":"Dextran sulphate\u2010Mg+2 precipitation procedure for quantitation of high\u2010density\u2010lipoprotein cholesterol","volume":"28","author":"Warnick G.R.","year":"1982","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03132.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.1.153"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02901.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(79)90138-0"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01797616"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1998.00460.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1998.00460.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2265.1998.00460.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1998.00460.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:27:30Z","timestamp":1694410050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1998.00460.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2265.1998.00460.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00460.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}